Linderholm Barbro K, Gruvberger-Saal Sofia, Fernö Mårten, Bendahl Pär-Ola, Malmström Per
Karolinska Biomic Center (KBC) Karolinska Institute, Stockholm, Sweden.
Breast. 2008 Oct;17(5):484-91. doi: 10.1016/j.breast.2008.02.010. Epub 2008 May 27.
We investigate the prognostic significance of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and S-phase fraction (SPF) for distant disease free survival (DDFS) in 219 premenopausal patients with node-negative breast cancer (NNBC). In univariate analysis significantly shorter DDFS was observed for patients with high VEGF (p=0.006), high uPA (p=0.001), and high SPF (p<0.001). The prognostic significance of VEGF varied over time being very strong for early relapses (0-2.25 years follow-up) (HR=7.9; p=0.006) while no difference was seen in the subsequent follow-up period (HR=1.3; p=0.62). In a series of bivariate analyses VEGF provided prognostic information during the whole observation period (0-72 months) in addition to age, tumour size, oestrogen receptor (ER), progesterone receptor (PgR), and uPA. Also this effect was more pronounced during the first follow-up period suggesting VEGF as a marker of early recurrences.
我们研究了促血管生成细胞因子血管内皮生长因子(VEGF)、尿激酶型纤溶酶原激活剂(uPA)、纤溶酶原激活剂抑制剂1(PAI-1)和S期分数(SPF)对219例绝经前淋巴结阴性乳腺癌(NNBC)患者远处无病生存期(DDFS)的预后意义。在单变量分析中,VEGF水平高(p=0.006)、uPA水平高(p=0.001)和SPF水平高(p<0.001)的患者DDFS明显缩短。VEGF的预后意义随时间变化,对于早期复发(随访0-2.25年)非常显著(HR=7.9;p=0.006),而在随后的随访期未见差异(HR=1.3;p=0.62)。在一系列双变量分析中,除年龄、肿瘤大小、雌激素受体(ER)、孕激素受体(PgR)和uPA外,VEGF在整个观察期(0-72个月)均提供预后信息。这种效应在首次随访期也更为明显,提示VEGF可作为早期复发的标志物。